Drugs indicated for headache treatment, such as CGRP monoclonal antibodies, may inflate reporting rates due to their therapeutic context, this circularity is unlikely to significantly bias results given the large dataset (9,536,756 reports) and diverse drug classes analyzed. This evidence concerns the gene CALCA and Headache.